In a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis Inducer

February 10, 2023

https://www.globenewswire.com/news-release/2023/02/10/2605843/0/en/In-a-KRAS-G12C-mutated-NSCLC-cell-line-Calu-1-Hillstream-BioPharma-Demonstrated-Significantly-Greater-Tumor-Inhibition-Combining-Pembrolizumab-an-anti-PD-1-antibody-and-HSB-1216-a-.html

Synergy and crosstalk between Ferroptosis and the Anti-PD-1 Pathways in KRAS G12C-mutated non-small cell lung cancer (NSCLC) cells

Lung cancer remains one of the leading causes of cancer-related deaths worldwide NSCLC accounts for approximately 80–85% of all cases of lung cancer

Read more at globenewswire.com

Related news for (HILS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.